Background

Introduction
Accessory spleen is a congenital defect which is caused by the fusion failure of the splenic anlage during embryology. As the name suggests, it is called intrapancreatic accessory spleen (IPAS) when the accessory spleen locates within the pancreas. IPAS is a benign lesion and rarely causes any symptom, and requires no surgical treatment unless it is associated with hematological disorders such as idiopathic thrombocytopenic purpura. Therefore it is crucial to differentiate IPAS with neoplastic diseases of the pancreas. There are only a few cases of IPAS reported according to the literature and most were identified only after surgical resection, which is performed for suspected endocrine tumor. Here we present a case of IPAS mimicking endocrine tumor of the pancreas with a history of splenectomy.
Case presentation
A 62-year-old female with a history of hepatic cirrhosis and portal hypertension for which she had been previously submitted to surgery and had spleen removed. Cholecystectomy was performed for the treatment of cholecystolithiasis at the same time. Before this admission, she presented with left upper quadrant discomfort for one week. The patient had no other complaints, such as nausea, vomiting, jaundice, or symptoms of hypoglycemia. Physical examination was unremarkable and laboratory data including peripheral blood counts, blood glucose and tumor biomarkers was within the normal range.
The ultrasonography to investigate her abdominal symptom revealed a 17 mm × 15 mm hypoechoic mass posterior to the stomach and superior to the left adrenal gland. The abdominal magnetic resonance image (MRI) further confirmed the 16 mm × 12 mm lesion in the pancreatic tail. Compared with the pancreatic tissue, the intrapancreatic mass presented lower intensity on T1-weighed MRI and higher intensity on both T2 and diffused weighed images (Fig. 1) . The lesion showed persisting enhancement during the late phases of dynamic MRI study. An extensive serum pancreatic hormone screen showed hormone levels within the normal limit after admission to our department. The computed tomography (CT) scans after her splenectomy two years ago were also reviewed and no bump was shown on both of the plain and enhanced scans (Fig. 1) . Thus, a non-functional pancreatic neuroendocrine tumor(PNET) was suspected after completion of this workup, and distal pancreatectomy was conducted because of the possibility of malignancy with the evidence that several slightly enlarged peripancreatic lymph nodes were revealed on the MRI.
The surgical specimen contained a well-demarcated dark-red soft nodule, 2.0 cm × 1.5 cm in size, surrounded by pancreatic tissue on macroscopic appearance. Microscopically, the nodule was composed of lymphoid follicles and sinusoid-like structures, and no apparent neoplastic component was founded (Fig. 2) . Thus, an intrapancreatic accessory spleen was confirmed by pathologic diagnosis. The patient recovered from surgery without complications and was discharged five days later. Both the platelet count and blood glucose level were within the normal limits on her follow-up visit three months after the operation.
Discussion
IPAS is an uncommon congenital abnormality of the spleen with the incidence around 2%. 1 It is a benign lesion without indication for operative intervention. However, in the majority of the cases reported from the literature, IPASs were resected surgically with no therapeutic effect, because they were difficult to make an accurate diagnosis preoperatively and were usually misdiagnosed as hypervascular pancreatic neoplasms, such as PNETs.
The incidence of PNETs ranges up to 15% of pancreatic neoplasms in surgical series. Nearly 70% of PNETs are classified as nonfunctional and all the PNET are malignant with the exception of minute incipient neoplasms that occur in some syndromes like type-1 multiple endocrine neoplasia. 2, 3 The initial imaging study used to identify a PNET is a high-quality contrast-enhanced multidetector CT scan. PENTs are typically hyperdense and spherical on the arterial phase of imaging. MRI is more sensitive in the detection of smaller PNETs. PNETs are especially well visualized on T1 and T2-weighted images with fat suppression and typically have high signal intensity on T2-weighted images. 4 The multimodality treatment for PENT includes surgery, hepatic-directed techniques and systemic chemotherapy. The overall 10-year survival rate of PNET ranges from 60% to 70% as reported. 3 It is essential to differentiate nonfunctional PNETs from IPASs because surgery is the preferable form of management for the former while the latter usually require no operative intervention. Unfortunately, there has been no special laboratory test with great usefulness to confirm or exclude the diagnosis of IPAS as yet. Current image techniques may provide useful information in the differentiation between the two kind of lesions. Compared with the spleen, the IPAS more frequently shows homogeneous enhancement and signal intensity than the PNET does on dynamic CT scans and MRI respectively. However, it remains difficult to accurately evaluate heterogeneous enhancement in IPAS smaller than 1 cm in diameter by using contrast-enhanced CT or conventional MRI. Jang et al. 5 evaluated the diffusion-weighted MRI (DW-MRI) imaging in differentiation of an IPAS from a small solid pancreatic tumor and found that combined review of both DW-MRI with apparent diffusion coefficient maps and conventional morphologic MRI can prevent the misdiagnosis of IPAS. Superparamagnetic iron oxideenhanced MRI is a sensitive and specific modality for the diagnosis of IPAS. Another noninvasive and specific test for detecting ectopic splenic tissue is 99mTc scintigraphy which is based on the phagocytosis of 99mTc-labeled red blood cells by macrophages of the reticuloendothelial system in the spleen. 6 Except for the non-invasive methods mentioned above, EUSguided fine-needle aspiration biopsy is an invasive approach to confirm the diagnosis of IPAS. Since Schreiner et al. reported the first case of IPAS diagnosed by EUS-FNA, there have been a few case reports of ectopic spleen diagnosed by EUS-FNA cytology. 7 The predominant cytological features of IPAS include a polymorphous population of lymphocytes, traversing small vascular structures, and CD8 positive immunostaining of endothelial cells in cell block sections. As immunostaining of CD8 is negative in systemic endothelial cell and hemangioma but specifically highlighted in endothelial cells of splenic sinuses, EUS-FNA with the aid of CD8 immunostaining may make it possible to diagnose IPAS preoperatively and thus avoid unnecessary surgery. 7, 8 Although a handful of IPASs have been reported, here we report the first case of IPAS after splenectomy according to the literature. The surgeons did not found any visible or palpable lesions during the previous operation. The IPAS had not been found until the patient underwent MRI for following examination after his splenectomy two years later. This phenomenon can be explained as compensation according to the literature. 9 In other words, the IPAS in our case did exist unvisiblly and enlarged after her splenectomy. We do not know whether the IPAS would continue to grow bigger if not been resected, but our rare case should raise the awareness of IPAS to avoid unnecessary surgery.
Conclusion
IPAS has no indication for operative intervention in the most cases, it is important to differentiate this benign lesion from pancreatic neoplasm to avoid unnecessary surgery. While the lesion is no more than 2.5 cm in diameter and other accessory spleens show around the splenic hilum, IPAS should be highly considered as a differential diagnosis.
